Burr Warns User Fee Renewal Could Be Difficult Without Performance Measure Improvements
This article was originally published in The Pink Sheet Daily
Executive Summary
Senator tells FDA Commissioner Hamburg that time to market is important metric during hearing dominated by questions about medical device review.